Alcon Manufacturing, Ltd.

Alcon Research, Ltd.

Novartis Ag

Alcon, Inc.

Nestec S.a.

Astellas Pharma Gmbh

Najam A Sharif

Hwang-Hsing Chen

Mark R Hellberg

Jesse Albert May

Thomas R Dean

Brenda W Griffin

Lukas Scheibler

David Archer Ellis

Peter G Klimko

Iok-Hou Pang

Elizabeth Offord Cavin

Keith D Combrink

David Ellis

Abdelmoula Namil

Andrew Rusinko

Andrea M A Pfeifer

Yvonne Tromvoukis

Bryon Severns

Gary W Williams

Colene D Drace

Curtis R Kelly

Suchismita Mohapatra

Ganesh Prasanna

Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention.

Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension

The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin Breceptor agonist to a patient in need thereof.

Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma

The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.

Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma

The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a non-peptide bradykinin agonist to a patient in need thereof.

Use of non-peptidic bradykinin receptor agonists to treat ocular hypertension and glaucoma

Methods for using hydroxyamino- and amino-substituted pyridine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of hydroxyamino- and amino-substituted pyridine analogs, are disclosed herein.

Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions

[object Object]

The present invention provides compositions and methods for treating glaucoma, ocular hypertension, and age-related macular degeneration. More specifically, the present invention describes the use of agents that down-regulate expression of tanis and/or p21genes to treat such disorders of the eye.

Method for treating glaucoma comprising administering &#x3b1;-lipoic acid

Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines, are disclosed herein.

(Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure

Compounds with 5HTreceptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.

Fused pyridazine derivatives are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

Methods of treating dry eye disorders

Compounds with 5HT receptor agonist activity useful for treating glaucoma, including lowering intraocular pressure. Compositions and methods for their use are also disclosed.

Serotonergic 5ht2 agonists for treating glaucoma

Methods and compositions for the antagonism of FP receptor-mediated biological responses are disclosed.

Growing community of inventors

Arlington, TX, United States of America

Najam A Sharif